Aripiprazole Augmentation in the Treatment of Military-Related PTSD with Major Depression: A retrospective chart review

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Richardson, J Don ^a,b,c   Fikretoglu, Deniz ^d,e   Liu, Aihua ^f   McIntosh, Diane ^g  

^a PARKWOOD HOSPITAL   (Canada)

^b National Centre for Operational Stress Injuries   (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^e DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CENTRAL STIMULANT AGENT; HYPNOTIC AGENT; MOOD STABILIZER; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRIPLE REUPTAKE INHIBITOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; QUINOLONE DERIVATIVE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGITATION; ARMY; ARTICLE; BECK DEPRESSION INVENTORY; CHECKLIST; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FATIGUE; FEMALE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MALE; MEDICAL RECORD REVIEW; OUTCOME VARIABLE; POSTTRAUMATIC STRESS DISORDER; RESTLESSNESS; RETROSPECTIVE STUDY; SIDE EFFECT; VETERAN; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; STATISTICS;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; QUINOLONES; RETROSPECTIVE STUDIES; STRESS DISORDERS, POST-TRAUMATIC; VETERANS;

EID: 79955962529     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-86     Document Type: Article

References (55)

1. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan: Mental health problems and barriers to care. New England Journal of Medicine 2004, 351:13-22. 10.1056/NEJMoa040603, 15229303.
2. Litz BT. The Psychological Demands of Peacekeeping. PTSD Clinical Quarterly 1996, 6(1):1-8.
3. Litz BT, King LA, King DW, Orsillo SM, Friedman M. Warriors as Peacekeepers: Features of the Somalia Experience and PTSD. J Consult Clin Psychol 1997, 65(6):1001-1010.
4. Litz BT, Orsillo SM, Friedman M, Erhlich P, Batres A. Posttraumatic Stress Disorder Associated with Peacekeeping Duty in Somalia for U.S. Military Personnel. Am J Psychiatry 1997, 154(5):178-184.
5. American Psychiatric Association Practice Guidelines for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. Am J Psychiatry 2004, American Psychiatric Association.
6. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4th-Text Revision edn. Washington, DC: Author 2001, American Psychiatric Association.
7. Iversen A, van Staden L, Hughes J, Browne T, Hull L, Hall J, Greenberg N, Rona R, Hotopf M, Wessely S, et al. The prevalence of common mental disorders and PTSD in the UK military: using data from a clinical interview-based study. BMC Psychiatry 2009, 9(1):68. 10.1186/1471-244X-9-68, 2774683, 19878538.
8. Richardson JD, Elhai J, Pedlar D. Association of PTSD and Depression with Medical and Specialist Care Utilization in Modern Peacekeeping Veterans in CanadaWith Health-Related Disabilities. J Clin Psychiatry 2006, 67:1240-1245. 10.4088/JCP.v67n0810, 16965202.
9. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 2004, 351(1):13-22. 10.1056/NEJMoa040603, 15229303.
10. Creamer M, Forbes D, Biddle D, Elliott P. Inpatient versus day hospital treatment for chronic, combat-related posttraumatic stress disorder: A naturalistic comparison. J Nerv Ment Dis 2002, 190:183-189. 10.1097/00005053-200203000-00007, 11923653.
11. Richardson JD, Long ME, Pedlar D, Elhai JD. Posttraumatic Stress Disorder and Health Related Quality Of Life (HRQol) among a Sample of Treatment- and Pension-Seeking deployed Canadian Forces Peacekeeping Veterans. Can J Psychiatry 2008,
12. Friedman M. Drug treatment for PTSD: answers and questions. Ann NY Acad Sci 1997, (821):359-371.
13. Shalev A, Bonne, Eth S. Treatment of posttraumatic stress disorder: A review. Psychosom Med 1996, (58):165-182.
14. Creamer M, Morris P, Biddle D, Elliott P. Treatment outcome in Australian veterans with combat-related posttraumatic stress disorder: A cause for cautious optimism?. J Trauma Stress 1999, 12:545-558. 10.1023/A:1024702931164, 10646175.
15. Johnson DR, Rosenheck R, Fontana A, Lubin H, Charney D, Southwick S. Outcome of intensive inpatient treatment for combat-related posttraumatic stress disorder. Am J Psychiatry 1996, 153:771-777.
16. Schoenfeld FB, Marmar CR, Neylan TC. Current Concepts in Pharmacotherapy for Posttraumatic Stress Disorder. Psychiatr Serv 2004, 55(5):519-531. 10.1176/appi.ps.55.5.519, 15128960.
17. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995, 52:1048-1060.
18. Forbes D, Creamer M, Hawthorne G, Allen N, McHugh T. Comorbidity as a predictor of symptom change after treatment in combat-related posttraumatic stress disorder. J Nerv Ment Dis 2003, 191:93-99.
19. Keane TM, Wolfe J. Comorbidity in post-traumatic stress disorder: An analysis of community and clinical studies. Journal of Applied Social Psychology 1990, 20:1776-1788.
20. Southwick S, Yehuda R, Giller EJ. Characterization of depression in war-related posttraumatic stress disorder. Am J Psychiatry 1991, 148:179-183.
21. Hamner MB, Frueh C, Ulmer HG, Arana GW. Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol Psychiatry 1999, 45:846-852. 10.1016/S0006-3223(98)00301-1, 10202572.
22. David D, Kutcher G, Jackson E. Psychotic symptoms in combat-related posttraumatic stress disorder. J Clin Psychiatry 1990, 60:29-32.
23. National Institute for Clinical Excellence Post-traumatic stress disorder (PTSD): The management of PTSD in adults and children in primary and secondary care. London, vol. NICE Clinical Guideline No. 26.: National Institute for Clinical Excellence 2005, National Institute for Clinical Excellence.
24. Van der Kolk B, Dreyfuss D, Micheals M, Shera D, Berkowitz R, Fisler R, Saxe G. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994, 55:517-522.
25. Hertzsberg M, Feldman M, Beckman J, Kudler H, Davidson J. Lack of efficacy for fluoxetine in PTSD: A placebo- controlled trial in combat veterans. Ann Clin Psychiatry 2000, 12:101-105.
26. Canadian Psychiatric Association Posttraumatic Stress Disorder. In Clinical Practice Guiselines Management of Anxiety Disorders. Can J Psychiatry 2006, 51(Suppl 2):57-63. Canadian Psychiatric Association.
27. Stein MB, Kline NA, Matloff JL. Adjunctive Olanzapine for SSRI-Resistant Combat-Related PTSD: A Double-Blind, Placebo-Controlled Study. Am J Psychiatry 2002, 159(10):1777-1779. 10.1176/appi.ajp.159.10.1777, 12359687.
28. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 2003, 18:1-8. 10.1097/00004850-200301000-00001, 12490768.
29. Monnelly EP, Ciraulo DA, Knapp CTK. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003, 23:193-196. 10.1097/00004714-200304000-00012, 12640221.
30. Bartzokis G, Freeman T, Roca V. Risperidone for patients with chronic combat related posttraumatic stress disorder. 154th Annual Meeting of the American Psychiatric Association 2001, New Orleans, LA.
31. Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. J Affect Disord 2009, 117(Suppl 1):S1-S2.
32. Villarreal G, Calais L, Cañive J, Lundy S, Pickard J, Toney G. Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Pchopharmacology Bulletin 2007, 40:6-18.
33. Robert S, Hamner MB, Durkalski VL, Brown MW, Ulmer HG. An Open-Label Assessment of Aripiprazole in the Treatment of PTSD. Psychopharmacol Bull 2009, 42(1):69-80.
34. Lambert MT. Aripiprazole in the management of post-traumatic stress disorder symptoms in returning Global War on Terrorism veterans. Int Clin Psychopharmacol 2006, 21(3):185-187. 10.1097/01.yic.0000185021.48279.00, 16528142.
35. McGavin J, Goa K. Aripiprazole. CNS Drugs 2002, 16:779-786. 10.2165/00023210-200216110-00008, 12383035.
36. Marder S, McQuade R, Stock E, Kaplita S, Marcus R, Safferman A, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia:safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003, 61:123-136. 10.1016/S0920-9964(03)00050-1, 12729864.
37. Swainston H, Perry C. Aripiprazole:a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004, 64:1715-1736. 10.2165/00003495-200464150-00010, 15257633.
38. Papakostas G, Shelton R, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007, 68:826-831. 10.4088/JCP.v68n0602, 17592905.
39. Nelson JC, Papakostas GI. Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials. Am J Psychiatry 2009, 166(9):980-991. 10.1176/appi.ajp.2009.09030312, 19687129.
40. Weathers FW, Litz BT, Herman DS, Huska JA, Keane TM. The PTSD checklist: Reliability, validity, & diagnostic utility. annual meeting of the International Society for Traumatic Stress Studies: October 1993; San Antonio, Texas 1993, International Society for Traumatic Stress Studies.
41. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
42. Ware JE, Snow KK, Kosinsk MBG. SF-36 Health Survey: Manual and lnterpretation Guide. 1993, Boston: New England Medical Center.
43. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Klauminser G, Charney DS, Keane TM. A clinician rating scale for assessing current and lifetime PTSD: The CAPS-1. Behavior Therapist 1990, 18:187-188.
44. Spitzer R, Kroenke K, Williams J. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999, 282(18):1737-1744. 10.1001/jama.282.18.1737, 10568646.
45. Beck AT. The diagnosis and management of depression. 1967, Philadelphia, Pennsylvania: University of Pennsylvania Press.
46. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988, 8:77-100.
47. Ware J, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. 1993, 2000. Lincoln, RI: Quality Metric Incorporated.
48. Ware J, Kosinski M, Bayliss M, McHorney C, Rogers W, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: Summary results from the Medical Outcomes Study. Med Care 1995, 33:AS264-AS279.
49. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
50. Anderson RJ, Gott BM, Sayuk GS, Freedland KE, Lustman PJ. Antidepressant Pharmacotherapy in Adults With Type 2 Diabetes. Diabetes Care 2010, 33(3):485-489. 10.2337/dc09-1466, 2827493, 20032276.
51. McDonald SD, Calhoun PS. The diagnostic accuracy of the PTSD Checklist: A critical review. Clin Psychol Rev 2010, 30(8):976-987. 10.1016/j.cpr.2010.06.012, 20705376.
52. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. 1996, San Antonio, Texas: Psychological Corporation.
53. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol 2008, 28(2):156-165. 10.1097/JCP.0b013e31816774f9, 18344725.
54. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, Mcquade RD, Carson WH, Adson D, Taylor L, Hazel J, et al. Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants. CNS spectrums 2009, 14(4):197-206.
55. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PKRN, Khan A. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry 2007, 68:843-853. 10.4088/JCP.v68n0604, 17592907.